News
Dianthus Therapeutics targets severe autoimmune diseases with DNTH103. Read more on DNTH's promise amid competitive ...
Roivant Sciences secures $5.2B for advancing late-stage drugs like IMVT-1402 & brepocitinib. Click here to read an analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback